Ingenuity Systems Licenses Pathways Analysis Software to Avalon Pharmaceuticals
January 10 2006 - 6:00AM
PR Newswire (US)
Avalon to Incorporate Ingenuity Pathways Analysis 3.0 Into Its Gene
Expression Platform to Facilitate Drug Discovery Efforts REDWOOD
CITY, Calif. and GERMANTOWN, Md., Jan. 10 /PRNewswire/ -- Ingenuity
Systems and Avalon Pharmaceuticals Inc. (Nasdaq: AVRX; ArcaEx(R))
today announced that they have entered into an agreement whereby
Avalon will license Ingenuity Pathways Analysis 3.0, enhancing
Avalon's drug and target discovery process. Avalon has a focused
program to harness the power of gene disruption signatures for the
isolation of drugs against previously "intractable" targets. The
Ingenuity Pathways Analysis 3.0 application is being applied to the
AvalonRx(R) platform in several selected therapeutic areas to
identify biomarkers, targets, and novel compounds. Ingenuity
Pathways Analysis 3.0 enables researchers to model, analyze and
understand the complex biological systems at the core of life
science research. With Ingenuity Pathways Analysis, scientists can
integrate their own biological discoveries into Ingenuity networks,
providing more effective computation and functional analysis. The
application is made particularly powerful because of the Ingenuity
Knowledge Base, which contains 1.4 million biological relationships
between genes and proteins, cells, tissues, and diseases, ensuring
researchers can query multiple reputable resources in a seamless
manner. About Ingenuity Systems(R) Ingenuity enables researchers to
model, analyze and understand complex biological systems
foundational to human health and disease. The Ingenuity products
include pathways analysis software and knowledge bases for
biologists and bioinformaticians, and enterprise knowledge
management infrastructure, content and services for leading
pharmaceutical and biotechnology companies. Ingenuity was founded
in 1998 and is headquartered in Redwood City, California with
offices in Germany, Switzerland, France, the United Kingdom, and
Japan. http://www.ingenuity.com/. Fully functional complimentary
trials of the NEW Ingenuity Pathways Analysis 3.0 are available to
qualified scientists at http://www.ingenuity.com/trial. About
Avalon Pharmaceuticals, Inc. Avalon Pharmaceuticals is a
biopharmaceutical company focused on the discovery and development
of small molecule therapeutics. Avalon seeks to discover and
develop novel therapeutics through the use of a comprehensive,
innovative and proprietary suite of technologies based upon
large-scale gene expression analysis which it calls AvalonRx(R).
Avalon Pharmaceuticals was established in 1999 and is headquartered
in Germantown, Maryland. http://www.avalonrx.com/ . Avalon
Pharmaceuticals, Inc.'s Forward Looking Statements: This
announcement contains, in addition to historical information,
certain forward- looking statements that involve risks and
uncertainties, in particular, related to statements concerning
Avalon's research and development activities and its collaboration
agreements. Such statements reflect the current views of Avalon
management and are based on certain assumptions. Actual results
could differ materially from those currently anticipated as a
result of a number of factors, risks and uncertainties. All forward
looking statements are qualified in their entirety by this
cautionary statement and the company undertakes no obligation to
revise or update this conference call to reflect events or
circumstances after the date hereof. DATASOURCE: Ingenuity Systems
CONTACT: Heidi Bullock, Director, Marketing of Ingenuity Systems,
+1-650-381-5150, or fax, +1-650-381-5190, or ; or Gary Lessing,
Chief Financial Officer of Avalon Pharmaceuticals, Inc.,
+1-301-556-9900, or fax, +1-301-556-9910; or Wendy Lau of Noonan
Russo, +1-212-845-4272, or , for Avalon Pharmaceuticals, Inc. Web
site: http://www.avalonrx.com/ Web site: http://www.ingenuity.com/
Copyright